Interim results from the Phase III SINDAS trial, looking at the addition of SBRT before tyrosine kinase inhibitor therapy for epidermal growth factor receptor (EGFR) mutated NSCLC, also found a progression-free survival and overall survival benefit (13). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.